Skip to main content
Terug
Watch Compare

aTYR PHARMA INC

Datakwaliteit: 100%
ATYR
Nasdaq Manufacturing Chemicals
€ 0,76
▼ € 0,04 (-4,68%)
Marktkapitalisatie: 74,75 M
Prijs
€ 0,76
Marktkapitalisatie
74,75 M
Dagbereik
€ 0,76 — € 0,80
52-Weeksbereik
€ 0,64 — € 7,29
Volume
951.207
Openen € 0,79
50D / 200D Gem.
€ 0,88
13,22% below
50D / 200D Gem.
€ 2,19
65,17% below

Quick Summary

Belangrijkste Punten

Revenue declined -63,28% annually over 5 years
Negative free cash flow of -62,06 M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 44,13%
Capital intensive — 40,53% of revenue goes to capex

Groei

Revenue Growth (5Y)
-63,28%
Onder sectorgemiddelde (1,82%)
Revenue (1Y)-19,15%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-95,59%
Onder sectorgemiddelde (-53,41%)
ROIC-69,30%
Net Margin-39009,47%
Op. Margin-40856,32%

Veiligheid

Debt / Equity
N/A
Current Ratio5,93
Interest CoverageN/A

Waardering

PE (TTM)
-1,01
Boven sectorgemiddelde (-1,48)
P/B Ratio0,93
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E -1,0 -1,5
P/B 0,9 1,6
ROE % -95,6 -53,4
Net Margin % -39009,5 -41,5
Rev Growth 5Y % -63,3 1,8
D/E — 0,3

ETFs Holding This Stock

AVSC logo AVSC Avantis U.S. Small Cap Equity ETF
0,00% weight
IWV logo IWV iShares Russell 3000 ETF
0,00% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) -19,15% Revenue Growth (3Y) -26,63%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -63,28% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 190.000,0 Net Income (TTM) -74,12 M
ROE -95,59% ROA -71,20%
Gross Margin N/A Operating Margin -40856,32%
Net Margin -39009,47% Free Cash Flow (TTM) -62,06 M
ROIC -69,30% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 5,93
Interest Coverage N/A Asset Turnover 0,00
Working Capital 77,34 M Tangible Book Value 80,24 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -1,01 Forward P/E N/A
P/B Ratio 0,93 P/S Ratio 393,44
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -83,02%
Market Cap 74,75 M Enterprise Value 68,60 M
Per Share
EPS (Diluted TTM) -0,80 Revenue / Share 0,00
FCF / Share -0,63 OCF / Share -0,63
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 40,53% FCF Conversion 83,74%
SBC-Adj. FCF N/A Growth Momentum 44,13

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 190.000,0 235.000,0 353.000,0 10,39 M 10,46 M
Net Income -74,12 M -64,02 M -50,39 M -45,34 M -33,77 M
EPS (Diluted) -0,80 -0,86 -0,94 -1,60 —
Gross Profit — — — — —
Operating Income -77,63 M -67,91 M -54,92 M -46,40 M -34,02 M
EBITDA — — — — —
R&D Expenses 60,22 M 54,37 M 42,29 M 42,81 M 23,26 M
SG&A Expenses — — — — —
D&A 664.000,0 708.000,0 592.000,0 232.000,0 475.000,0
Interest Expense — — — — —
Income Tax 0,0 0,0 0,0 0,0 0,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 93,00 M 96,83 M 120,65 M 95,79 M 115,54 M
Total Liabilities — — — — —
Shareholders' Equity 67,48 M 70,02 M 90,66 M 71,46 M 109,30 M
Total Debt — — — — —
Cash & Equivalents 10,74 M 11,06 M 22,54 M 9,98 M 2,34 M
Current Assets 80,24 M 81,95 M 102,99 M 80,87 M 113,57 M
Current Liabilities 15,15 M 14,97 M 16,42 M 13,86 M 6,01 M